Skip to main
  1. Stocks
  2. Alumis Inc
  3. Forecast
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis is supported by a compelling TYK2-focused pipeline, with envudeucitinib showing competitive clinical efficacy in psoriasis and a 54% PASI100 response rate at wk48, the highest reported among oral PsO programs, while NDA submission remains on track for 4Q26. The company’s thesis is further strengthened by the validation of TYK2 in PsO and SLE, plus the optionality from A-005, a CNS-penetrant candidate that could extend the platform into neuroinflammatory and neurodegenerative diseases. Despite commercial questions around twice-daily dosing, the profile still suggests meaningful upside versus Sotyktu and supports a favorable long-term outlook ahead of key catalysts in 2H26, 4Q26, 1H27, and 2027.

Bears say

Alumis is facing a deteriorating fundamental setup because envudeucitinib, despite strong psoriasis efficacy signals, must compete against once-daily incumbents and may enter the U.S. after Icotyde and zasocitinib, limiting commercial differentiation. The SLE program is a larger concern since the 408-patient Phase 2b LUMUS trial missed its primary and secondary endpoints in the overall population, leaving regulatory and pivotal-study requirements unclear and potentially delaying approval by 3-4 years if more trials are needed. Financially, cash fell to $431.3M from $502.3M, the company added a going-concern qualification, and management expects to raise capital before launch, creating dilution risk while 3Q26 net loss remained $94.9M.

Alumis Inc (ALMS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Alumis Inc (ALMS) Analyst Forecast & Price Prediction

Get the latest Alumis Inc (ALMS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Alumis Inc (ALMS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Alumis Inc (ALMS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Alumis Inc (ALMS) Analyst Forecast & Price Prediction

Get the latest Alumis Inc (ALMS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Alumis Inc (ALMS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ALMS stock data and trends